BofA raised the firm’s price target on Amphastar (AMPH) to $32 from $28 and keeps a Neutral rating on the shares after increasing near-term forecasts to reflect the recent generic Venofer approval. Generic Venofer “looks like a good, but not great, generic product due to competitive dynamics at market formation,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights
- Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating
- Amphastar announced FDA approval of iron sucrose injection
- Needham upgrades Amphastar on valuation post AMP-002 approval
- Amphastar upgraded to Buy from Hold at Needham